The prognosis of patients treated with everolimus for advanced ER‐positive, HER2‐negative breast cancer is driven by molecular features

• Váldodahkkit: Hélène Salaün (Dahkki), Lounes Djerroudi (Dahkki), Laura Haik (Dahkki), Anne Schnitzler (Dahkki), Guillaume Bataillon (Dahkki), Gabrielle Deniziaut (Dahkki), Ivan Bièche (Dahkki), Anne Vincent‐Salomon (Dahkki), Marc Debled (Dahkki), Paul Cottu (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wiley, 2024-05-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract Everolimus is widely used in patients with advanced ER‐positive, HER2‐negative breast cancer. We looked at alterations in the PIK3CA/AKT/mTOR pathway in a multicenter cohort as potential biomarkers of efficacy. Patients with advanced ER‐positive, HER2‐negative breast cancer treated with eve...